pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 41 Non-oncology: 27
Oncology: 14
Under Consideration for Negotiation 15 Non-oncology: 7
Oncology: 8
Completed Negotiations 819 With Letter of Intent: 711
Without agreement: 108
Negotiations That Were Not Pursued 110

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Noyada Ethypharm Inc. Multiple Indications
Lumakras Amgen Canada Inc. Advanced non-small cell lung cancer, KRAS G12C-mutated
Otulfi Fresenius Kabi Canada Ltd. Multiple Indications
Yesintek Biocon Biologics Canada Inc. Multiple Indications
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Avtozma Celltrion Healthcare Canada Ltd. Multiple Indications
Symtuza Janssen Inc. HIV-1 Infection
Bildyos Organon Canada Inc. Multiple Indications
Bilprevda Organon Canada Inc. Multiple Indications
Oslya Mantra Pharma Multiple Indications
Osdenza Apotex Inc. Osteoporosis
Idenos Apotex Inc. Multiple Indications
Obodence Samsung Bioepis Co., Ltd. Multiple Indications

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Keytruda Merck Canada Inc. In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Crysvita Kyowa Kirin Canada, Inc. X-Linked Hypophosphatemia
Omlyclo Celltrion Healthcare Canada Ltd. Multiple Indications
Evkeeza Ultragenyx Pharmaceutical Inc. Homozygous Familial Hypercholesterolemia
Ultomiris Alexion Pharma GmbH Generalized myasthenia gravis (gMG)
Ultomiris Alexion Pharma GmbH Neuromyelitis optica spectrum disorder (NMOSD)
Fruzaqla Takeda Canada Inc. For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother
Vemlidy Gilead Sciences Canada Inc. chronic Hepatitis B virus

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Winlevi Sun Pharma Canada Inc. Acne Vulgaris